Co-developer of Cassava’s potential Alzheimer’s drug cited for ‘egregious misconduct’

United States News News

Co-developer of Cassava’s potential Alzheimer’s drug cited for ‘egregious misconduct’
United States Latest News,United States Headlines
  • 📰 NewsfromScience
  • ⏱ Reading Time:
  • 73 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 32%
  • Publisher: 51%

City University of New York’s Hoau-Yan Wang couldn’t provide original data to refute allegations of image manipulation, university says

Cassava Sciences, a biotech company whose work on the experimental Alzheimer’s drug simufilam has been heavily criticized and is the subject of ongoing federal probes, has suffered another blow. A much-anticipated investigation by the City University of New York has accused neuroscientist Hoau-Yan Wang, a CUNY faculty member and longtime Cassava collaborator, of scientific misconduct involving 20 research papers.

The CUNY investigation into Wang began in the fall of 2021, in response to allegations from other investigators that were forwarded by the Office of Research Integrity , the federal entity that oversees work funded by the National Institutes of Health. NIH provided millions of dollars for work by Wang and Burns, including about $1.2 million to Wang since December 2020. The investigation was not completed until this year, in May, according to emails obtained by.

It appears likely that no primary data and no research notebooks pertaining to the 31 allegations exist. together since the mid-2000s. Their studies of the brain’s opioid receptors were applied to developing a pain drug that reached clinical trials but never won Food and Drug Administration approval. The collaborators shifted their efforts to the possible influence on Alzheimer’s of filamin-A, a protein that provides cellular scaffolding for neurons and other cells.

Cassava conducted relatively small phase 2 trials of the drug. Based on what it said were promising results, it launched the phase 3 trials needed to win FDA approval. One of Cassava’s phase 3 trials to treat mild-to-moderate Alzheimer’s has enrolled more than 800 volunteers. The company says that by December it will complete enrollment of nearly 1100 more patients for a second phase 3 trial. After the petition, FDA declined to pause those trials, but reserved the right to do so.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsfromScience /  🏆 515. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Dallas' Old City Park city landmark designation causes clashDallas' Old City Park city landmark designation causes clashBreaking news and the latest headlines from North Texas, including Dallas, Plano, Frisco, McKinney, Arlington, Irving and beyond. Politics, education, transportation, housing, crime and more.
Read more »

Dallas City Council appoints Tammy Palomino as permanent city attorneyDallas City Council appoints Tammy Palomino as permanent city attorneyBreaking news and investigations on politics and policy in Texas, from City Council to the State Legislature. Includes Dallas, Plano, Frisco, McKinney, Arlington, Irving and beyond.
Read more »

Misinformation about Israel-Gaza war is plentiful, but Musk’s X is the most egregiousMisinformation about Israel-Gaza war is plentiful, but Musk’s X is the most egregiousAP Breaking News & Headlines. Find the latest national, world and local PA news from the Associated Press. Get top news stories on Weather, Politics, Sports, Business, Entertainment, Health & more from AP News Wire. Browse AP Photos & Videos at PennLive.com.
Read more »

Social media awash in misinformation about Israel-Gaza war, but X is perhaps the most egregiousSocial media awash in misinformation about Israel-Gaza war, but X is perhaps the most egregiousThe Israel-Hamas war has underscored how the platform now transformed into X has become not only unreliable but is actively promoting falsehoods.
Read more »

Musk's X egregious in its misinformation about Israel-Gaza war; EU threatens finesMusk's X egregious in its misinformation about Israel-Gaza war; EU threatens finesThe Israel-Hamas war has underscored how the platform formerly known as Twitter, now transformed into X, has become not only unreliable but is actively promoting falsehoods.
Read more »

Carlsbad OKs new pay packages for city manager and city attorneyCarlsbad OKs new pay packages for city manager and city attorneyCity manager gets $30,000 stipend, city attorney gets 3.6% salary raise and boost in life insurance benefit
Read more »



Render Time: 2025-04-13 15:14:56